Jelinek DF - Search Results

1

ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype.

Nolz JC, Tschumper RC, Pittner BT, Darce JR, Kay NE, Jelinek DF. Nolz JC, et al. Among authors: jelinek df. Leukemia. 2005 Jun;19(6):1018-24. doi: 10.1038/sj.leu.2403726. Leukemia. 2005. PMID: 15800671

2

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.

Zent CS, Secreto CR, LaPlant BR, Bone ND, Call TG, Shanafelt TD, Jelinek DF, Tschumper RC, Kay NE. Zent CS, et al. Among authors: jelinek df. Leuk Res. 2008 Dec;32(12):1849-56. doi: 10.1016/j.leukres.2008.05.014. Epub 2008 Jun 27. Leuk Res. 2008. PMID: 18584865 Free PMC article. Clinical Trial.

3

B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules.

Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF. Kay NE, et al. Among authors: jelinek df. Leukemia. 2002 May;16(5):911-9. doi: 10.1038/sj.leu.2402467. Leukemia. 2002. PMID: 11986954

4

Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach.

French JD, Tschumper RC, Jelinek DF. French JD, et al. Among authors: jelinek df. Leukemia. 2002 Jun;16(6):1189-96. doi: 10.1038/sj.leu.2402516. Leukemia. 2002. PMID: 12040452

5

Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells.

Arendt BK, Velazquez-Dones A, Tschumper RC, Howell KG, Ansell SM, Witzig TE, Jelinek DF. Arendt BK, et al. Among authors: jelinek df. Leukemia. 2002 Oct;16(10):2142-7. doi: 10.1038/sj.leu.2402714. Leukemia. 2002. PMID: 12357369

6

VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.

Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. Lee YK, et al. Among authors: jelinek df. Leukemia. 2005 Apr;19(4):513-23. doi: 10.1038/sj.leu.2403667. Leukemia. 2005. PMID: 15703780

7

CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation.

Pittner BT, Shanafelt TD, Kay NE, Jelinek DF. Pittner BT, et al. Among authors: jelinek df. Leukemia. 2005 Dec;19(12):2264-72. doi: 10.1038/sj.leu.2403975. Leukemia. 2005. PMID: 16208411

8

Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX.

Walters DK, Wu X, Tschumper RC, Arendt BK, Huddleston PM, Henderson KJ, Dispenzieri A, Jelinek DF. Walters DK, et al. Among authors: jelinek df. Leukemia. 2011 Aug;25(8):1344-53. doi: 10.1038/leu.2011.94. Epub 2011 May 13. Leukemia. 2011. PMID: 21566653 Free PMC article.

9

Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells.

Wu X, Tschumper RC, Jelinek DF. Wu X, et al. Among authors: jelinek df. Leukemia. 2013 Nov;27(11):2264-7. doi: 10.1038/leu.2013.155. Epub 2013 May 20. Leukemia. 2013. PMID: 23685408 Free PMC article. Clinical Trial. No abstract available.

10

VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.

Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. Lee YK, et al. Among authors: jelinek df. Blood. 2004 Aug 1;104(3):788-94. doi: 10.1182/blood-2003-08-2763. Epub 2004 Mar 2. Blood. 2004. PMID: 14996703 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

188 results

Search Page